- Home
- HFBL vs LEXX Comparison
HFBL vs LEXX Comparison
Compare HFBL & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFBL
- LEXX
- Stock Information
- Founded
- HFBL 1924
- LEXX 2004
- Country
- HFBL United States
- LEXX Canada
- Employees
- HFBL N/A
- LEXX N/A
- Industry
- HFBL Savings Institutions
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- HFBL Finance
- LEXX Health Care
- Exchange
- HFBL Nasdaq
- LEXX Nasdaq
- Market Cap
- HFBL 39.4M
- LEXX 39.1M
- IPO Year
- HFBL N/A
- LEXX N/A
- Fundamental
- Price
- HFBL $12.82
- LEXX $1.95
- Analyst Decision
- HFBL
- LEXX Strong Buy
- Analyst Count
- HFBL 0
- LEXX 2
- Target Price
- HFBL N/A
- LEXX $11.00
- AVG Volume (30 Days)
- HFBL 625.0
- LEXX 245.8K
- Earning Date
- HFBL 01-27-2025
- LEXX 01-10-2025
- Dividend Yield
- HFBL 4.06%
- LEXX N/A
- EPS Growth
- HFBL N/A
- LEXX N/A
- EPS
- HFBL 1.09
- LEXX N/A
- Revenue
- HFBL $19,727,000.00
- LEXX $496,923.00
- Revenue This Year
- HFBL N/A
- LEXX $20.39
- Revenue Next Year
- HFBL N/A
- LEXX $113.25
- P/E Ratio
- HFBL $11.80
- LEXX N/A
- Revenue Growth
- HFBL N/A
- LEXX 77.63
- 52 Week Low
- HFBL $10.60
- LEXX $1.36
- 52 Week High
- HFBL $14.60
- LEXX $6.85
- Technical
- Relative Strength Index (RSI)
- HFBL 49.13
- LEXX 40.43
- Support Level
- HFBL $12.55
- LEXX $1.87
- Resistance Level
- HFBL $13.00
- LEXX $2.04
- Average True Range (ATR)
- HFBL 0.02
- LEXX 0.22
- MACD
- HFBL 0.00
- LEXX -0.02
- Stochastic Oscillator
- HFBL 28.72
- LEXX 40.74
About HFBL Home Federal Bancorp Inc. of Louisiana
Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.